IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Potential link between Helicobacter pylori seropositivity and macrophage migration inhibitory factor in patients with myocardial infarction underwent primary percutaneous coronary intervention

Author: FEYAN ABDULLAH, RUQAYA MOHAMMED GHAREEB TAHER AL-BARZINJI
Abstract: Objective: To determine the possible link between helicobacter pylori (HP) seropositivity and macrophage migration inhibitory factor (MIF) level in myocardial infarction (MI) patients admitted for primary percutaneous coronary intervention (PPCI). Method: This case control study was carried out on 100 MI, 38 stable angina pectoris (SAP), and 38 subjects as control who admitted to surgical specialty hospital-cardiac centre in Erbil City, Iraq from January to December 2017. Levels of MIF and anti-HP IgG, IgA, and IgM were detected by enzyme linked immunosorbent assay (ELISA). Polymerase chain reaction (PCR) was done to detect HP 16SrRNA in those samples with IgM+ and/or IgG+IgA+. Results: Anti-Hp-IgG was positive in 68%, and 55.26% of MI, and SAP patients respectively. A higher proportion of HP seropositivity was observed in control group (84.21%). Molecular analysis showed no positive result for HP genomic material. MIF level was insignificantly differed between seropositive and seronegative MI patients (p>0.05). Seropositive MI group had higher MIF level compared to seropositive and negative control groups (p<0.05). Conclusion: Result of current study suggested that HP does not have direct role in MI elevated MIF, consequently demonstrated secondary contribution of HP in the development and progression of MI through low grade inflammatory response represented by insignificant elevation of MIF, and other inflammatory biomarkers (hsCRP, and fibrinogen).
Keyword: MIF, PPCI
DOI: https://doi.org/10.31838/ijpr/2019.11.02.109
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
Pharmacovigilance: Current Scenario and Emerging Trends

National Conference sponsored by GUJCOST on 03.08.2019 at SNLPCP, Umrakh

Download Brochure
News & Events
0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477